Drug Profile
Research programme: influenza virus strain H5N1 clade 2 vaccine - sanofi pasteur
Alternative Names: H5N1 clade 2.2 strain vaccine - sanofi pasteur; Pandemic H5N1 clade 2.2 strain vaccine - sanofi pasteurLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer Sanofi Pasteur
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Injection)
- 18 Mar 2009 Development of H5N1 clade 2 strain vaccine is ongoing